Screener
Axsome Therapeutics AXSM Interest Income
Interest Income at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:InvestmentIncomeNet.
The source filing: Axsome Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 5:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204274
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Intangible asset amortization | 1,572 | 1,572 |
| Total operating expenses | 254,560 | 178,445 |
| Loss from operations | (63,357) | (56,982) |
| Interest expense, net | (1,185) | (2,431) |
| Loss before income taxes | (64,542) | (59,413) |
| Income tax expense | — | — |
| Net loss | $(64,542) | $(59,413) |
| Net loss per common share, basic and diluted | $(1.26) | $(1.22) |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Axsome Therapeutics's interest income?
- Axsome Therapeutics (AXSM) reported interest income of -$1.19M in Q1 2026.
- How has Axsome Therapeutics's interest income changed year-over-year?
- Axsome Therapeutics's interest income increased by 51.3% year-over-year, from -$2.43M to -$1.19M.
- What is the long-term trend for Axsome Therapeutics's interest income?
- Over 4 years (2021 to 2025), Axsome Therapeutics's interest income has grown at a 3.6% compound annual growth rate (CAGR), from -$5.7M to -$6.56M.
- What does interest income mean?
- Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.
Ask your AI about Axsome Therapeutics's interest income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude